Assessing AbbVie: Insights From 17 Financial Analysts
Assessing AbbVie: Insights From 17 Financial Analysts
評估艾伯維公司：來自17位財務分析師的見解
The standing of AbbVie...AbbVie (NYSE:ABBV) underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
艾伯維公司（紐交所：ABBV）在上個季度接受了17位分析師的分析，顯示出從看好到看淡的觀點多樣性。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表提供了分析師最近評級的簡明概述，提供了過去30天內情緒變化的洞察，並與前幾個月進行了比較，以便全面了解。
Analysts have set 12-month price targets for AbbVie, revealing an average target of $211.24, a high estimate of $231.00, and a low estimate of $191.00. This current average has increased by 0.55% from the previous average price target of $210.08.
分析師爲艾伯維公司設定了12個月的價格目標，顯示出平均目標爲211.24美元，最高估計爲231.00美元，最低估計爲191.00美元。當前的平均值比之前的平均價格目標210.08美元增加了0.55%。
Diving into Analyst Ratings: An In-Depth Exploration
深入探討分析師評級：分析師評級的深度探討
The standing of AbbVie...
通過對近...
登入免費觀看全文
登入/註冊
熱門討論
特朗普2.0時代開啓，全球股市新風口在哪裏？
▪️加密貨幣政策能否利好crypto? ▪️關稅政策能否利好中概等海外資產？ ▪️在特朗普政策下，有哪些投資機會值得關注？
標普500
01/13 20:53
離川普上臺只有7天了～